Ketorolac Use in Pain Management

Critical Safety Concerns and Alternatives

• The American College of Physicians recommends that patients with marginal baseline kidney function, such as those with sickle cell crisis, are at elevated risk of acute renal failure when using ketorolac 1
• Patients ≥60 years of age, those with compromised fluid status, pre-existing renal impairment, or on concomitant nephrotoxic drugs are at increased risk of renal complications when using ketorolac 1, 2
• Treatment duration of ketorolac must be limited to ≤5 days with a maximum daily dose of 120 mg in adults to minimize renal complications 1
• Oral NSAIDs, such as ibuprofen or naproxen, are recommended as first-line therapy for mild to moderate pain, with fewer side effects than parenteral options 3
• Acetaminophen combined with oral NSAIDs provides effective analgesia for many acute pain conditions without the severe restrictions of ketorolac 3
• Acetaminophen is recommended as a front-line agent with moderate efficacy and added antipyretic effects, requiring only dose adjustments in hepatic cirrhosis 4
• The American Society of Anesthesiologists suggests that oral opioids, such as hydrocodone or oxycodone, provide longer-acting analgesia with less frequent dosing for moderate to severe pain 4
• Gabapentinoids are appropriate for neuropathic pain components, according to the American Academy of Neurology 4
• Ketorolac provides opioid-level analgesia without respiratory depression, sedation, or dependence issues, typically in postoperative settings 3
• A single 30-mg IV dose of ketorolac shows comparable efficacy to morphine 4 mg IV for procedural pain, as recommended by the American Society of Regional Anesthesia and Pain Medicine 2